PEO1Homo sapiens (Human)Cancer cell line
Also known as: PEO, PEO-1, PE01
Quick Overview
Human ovarian cancer cell line with BRCA2 mutations and platinum resistance.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_2686 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Ascites[UBERON:UBERON_0007795] |
Donor Information
| Age Category | Unknown |
|---|---|
| Sex | Female |
Disease Information
| Disease | Hereditary breast and ovarian cancer syndrome |
|---|---|
| Lineage | Ovary/Fallopian Tube |
| Subtype | Serous Ovarian Cancer |
| OncoTree Code | SOC |
DepMap Information
| Source Type | Sigma-Aldrich |
|---|---|
| Source ID | ACH-001630_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Gly244Asp (c.731G>A) | Unspecified | - | PubMed=28273451 |
| MutationSimple | BRCA2 | p.Tyr1655Ter (c.4965C>G) (5193C>G) | Hemizygous | - | from parent cell line PEO1 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Wang P., Birrer M.J., Paulovich A.G.
Cell Rep. Med. 2:100471.1-100471.32(2021).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.
Nat. Commun. 7:12645.1-12645.14(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
Noonan A.M., Annunziata C.M.
Gynecol. Oncol. 142:332-340(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Helleman J.
PLoS ONE 9:E103988-E103988(2014).
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mills G.B., Hennessy B.T.
Mol. Oncol. 7:567-579(2013).
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Lessey B.A., Jordan V.C., Bradford A.P.
Gynecol. Oncol. 127:241-248(2012).
Genomic complexity and AKT dependence in serous ovarian cancer.";
Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.
Cancer Discov. 2:56-67(2012).
The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.
Batty E.M., Pole J.C.M., Langdon S.P., Edwards P.A.W., Brenton J.D.
J. Pathol. 226:703-712(2012).
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
Langdon S.P., Huntsman D.G., Brenton J.D.
Oncogene 29:4905-4913(2010).
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
Langdon S.P., Wurz K., Higgins J., Villegas E., Taniguchi T.
Cancer Res. 69:6381-6386(2009).
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.
Cancer Res. 57:850-856(1997).
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.
Mullen P., Ritchie A., Langdon S.P., Miller W.R.
Int. J. Cancer 67:816-820(1996).
Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient.
Adams D.J., Lewis A.D., Scott A.R.R., Smyth J.F.
Int. J. Cancer 39:695-702(1987).
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F.
Cancer Res. 48:6166-6172(1988).